IBEX Limited Q4 2026 Earnings Call Summary

IBEX Limited Q4 2026 Earnings Call Summary – Moby Strategic Performance and Operational Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here. Achieved a sixth consecutive quarter of double-digit revenue growth, driven by…


IBEX Limited Q4 2026 Earnings Call Summary
IBEX Limited Q4 2026 Earnings Call Summary
IBEX Limited Q4 2026 Earnings Call Summary – Moby

Strategic Performance and Operational Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.

  • Achieved a sixth consecutive quarter of double-digit revenue growth, driven by a ‘flywheel’ effect where operational outperformance leads to rapid market share gains from traditional BPO competitors.

  • Surpassed the $100 million annual revenue target for the HealthTech vertical, reaching $114 million through purely organic growth and expansion with large payers and specialty providers.

  • Formalized a strategic partnership with Sierra AI to deploy AI agents that achieve resolution rates exceeding 20% to 40% while maintaining customer satisfaction scores on par with or exceeding those of human agents.

  • Demonstrated a ‘land and expand’ model where leading with AI solutions (e.g., BJ’s Wholesale) serves as a Trojan horse to subsequently win traditional human agent business.

  • Leveraged a world-class employee net promoter score of 82 to create a competitive moat, asserting that high employee engagement directly correlates to the company’s ability to outperform peers operationally.

  • Successfully transitioned the perceived threat of AI into a growth vector by using AI agents to capture previously unhandled call volume and convert it into incremental sales opportunities for human agents.

Fiscal Year 2027 Outlook and Strategic Priorities

  • Guidance for FY27 assumes 9% to 11% revenue growth, supported by a strong pipeline in HealthTech and the rapid deployment capabilities of AI agent solutions.

  • Management expects adjusted EBITDA margins to return to expansion in Q1 FY27 following temporary margin pressure from new client implementation costs and geographic work shifts.

  • Anticipates that AI agent deployments will reach full scale significantly faster than traditional human agent ramps, potentially shortening the timeline from contract win to revenue recognition.

  • Strategic focus remains on shifting delivery to high-margin offshore regions (currently 50% of revenue) and expanding digital/omnichannel services which now represent 82% of total revenue.

  • Normalized tax rate is projected to stabilize between 20% and 22% for the coming year, following one-time discrete benefits in the current period.

Structural Adjustments and Risk Factors

  • Recorded $2 million in lease termination and severance expenses related to a strategic structural shift of work from nearshore to offshore delivery centers.

  • Noted a temporary headwind from higher fuel prices impacting utility and transportation expenses, particularly within offshore operations.

  • Exited ’emerging growth’ status after five years as a public company, initiating the SOC certification process for financial reporting and disclosure controls.

  • Renewed revolving credit facilities with HSBC through October 2029, providing $76 million in total capacity to support growth initiatives.

Source link